Alexion Halts US Ultomiris Royalties, Xencor Disagrees and Updates Financial Outlook

summarizeSummary

Xencor announced that its licensee, Alexion Pharmaceuticals, will no longer pay US royalties for Ultomiris, impacting $100-$120 million in anticipated revenue, leading Xencor to dispute the decision while reaffirming its cash runway into mid-2028.

check_boxKey Events

• US Royalty Payments Halted

  Alexion Pharmaceuticals, Inc. informed Xencor that it will no longer pay royalties for sales of Ultomiris® in the United States, effective March 2, 2026.

• Significant Revenue Loss Anticipated

  This cessation impacts an estimated $100 million to $120 million in aggregate royalties Xencor previously expected to receive through 2028 from US sales.

• Legal Dispute Imminent

  Xencor disagrees with Alexion's position and is actively evaluating its options, suggesting a potential legal challenge to enforce the licensing agreement.

• Cash Runway Reaffirmed

  Despite the royalty dispute, Xencor updated its financial guidance, projecting $380 million to $400 million in cash by year-end 2026 and maintaining sufficient cash resources to fund operations into mid-2028.

auto_awesomeAnalysis

Alexion Pharmaceuticals, a licensee, has informed Xencor that it will cease all future royalty payments for sales of Ultomiris in the United States, citing no further obligations. This decision directly impacts Xencor's previously announced expectation of receiving an additional $100 to $120 million in US royalties through 2028. Xencor strongly disagrees with Alexion's position and is actively evaluating its legal options, indicating a potential dispute over the licensing agreement. Despite this significant loss of anticipated revenue, Xencor has updated its financial guidance, reaffirming its cash runway into mid-2028 with an expected $380 million to $400 million in cash by the end of 2026. This event introduces a material financial uncertainty and potential litigation, although the company's near-term liquidity appears stable.